Monkasta (Montelukast)

Montelukast blocks the CysLT1 receptor, preventing cysteinyl leukotrienes from binding. By inhibiting these inflammatory mediators, it reduces bronchoconstriction, mucus production, and vascular leakage in the airways, leading to improved breathing and reduced allergic inflammation.

The specific dose of Monkasta is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for montelukast in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against any possible risks before prescribing Monkasta to pregnant or nursing individuals. Consultation with a healthcare provider is essential.

To request Monkasta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monkasta (montelukast) belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a once‑daily tablet, but it may be used alongside other controller medications for optimal control.

Monkasta should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Monkasta is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush, chew, or split it unless specifically instructed.

Serious adverse events, although rare, can include severe allergic reactions such as rash, swelling or anaphylaxis, as well as mood changes like depression, anxiety, or suicidal thoughts. Liver enzyme elevations have also been reported; patients should report any unusual symptoms promptly.

Monkasta is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Patients with uncontrolled severe liver disease should avoid use, and it should be prescribed with caution in those with a history of psychiatric disorders.